发布求助
文献互助 智能选刊 最新文献

Im Fokus Onkologie最新文献

筛选
英文 中文
CAR-T-Zell-Therapie beim multiplen Myelom früher erwägen? 更早地考虑使用 CAR T 细胞疗法治疗多发性骨髓瘤？
Im Fokus Onkologie Pub Date : 2024-04-01 DOI: 10.1007/s15015-024-3758-9
E. Oberhofer
{"title":"CAR-T-Zell-Therapie beim multiplen Myelom früher erwägen?","authors":"E. Oberhofer","doi":"10.1007/s15015-024-3758-9","DOIUrl":"https://doi.org/10.1007/s15015-024-3758-9","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140779390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sport hilft bei Chemotherapie-induzierter Neuropathie 运动有助于缓解化疗引起的神经病变
Im Fokus Onkologie Pub Date : 2024-04-01 DOI: 10.1007/s15015-024-3771-z
Oliver Növermann, J. Neumaier
{"title":"Sport hilft bei Chemotherapie-induzierter Neuropathie","authors":"Oliver Növermann, J. Neumaier","doi":"10.1007/s15015-024-3771-z","DOIUrl":"https://doi.org/10.1007/s15015-024-3771-z","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140783344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impfung schützt vor Rezidiv beim Hochrisiko-Melanom 疫苗接种可预防高危黑色素瘤复发
Im Fokus Onkologie Pub Date : 2024-04-01 DOI: 10.1007/s15015-024-3764-y
Kathrin von Kieseritzky
{"title":"Impfung schützt vor Rezidiv beim Hochrisiko-Melanom","authors":"Kathrin von Kieseritzky","doi":"10.1007/s15015-024-3764-y","DOIUrl":"https://doi.org/10.1007/s15015-024-3764-y","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140793211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Länger leben mit Vitaminen bei Darmkrebs? Viel hilft nicht viel 服用维生素治疗肠癌能活得更长？多吃无益
Im Fokus Onkologie Pub Date : 2024-04-01 DOI: 10.1007/s15015-024-3818-1
T. Müller
{"title":"Länger leben mit Vitaminen bei Darmkrebs? Viel hilft nicht viel","authors":"T. Müller","doi":"10.1007/s15015-024-3818-1","DOIUrl":"https://doi.org/10.1007/s15015-024-3818-1","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140767070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inhibitoren des Ubiquitin-Proteasom-Systems 泛素-蛋白酶体系统抑制剂
Im Fokus Onkologie Pub Date : 2024-04-01 DOI: 10.1007/s15015-024-3817-2
Sabrina Kempe
{"title":"Inhibitoren des Ubiquitin-Proteasom-Systems","authors":"Sabrina Kempe","doi":"10.1007/s15015-024-3817-2","DOIUrl":"https://doi.org/10.1007/s15015-024-3817-2","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140771359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ramucirumab: wirksame bei Magenkarzinomen und NSCLC Ramucirumab：对胃癌和 NSCLC 有效
Im Fokus Onkologie Pub Date : 2024-04-01 DOI: 10.1007/s15015-024-3802-9
Miriam Sonnet
{"title":"Ramucirumab: wirksame bei Magenkarzinomen und NSCLC","authors":"Miriam Sonnet","doi":"10.1007/s15015-024-3802-9","DOIUrl":"https://doi.org/10.1007/s15015-024-3802-9","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140761517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Den „Datenschatz“ der Krebsregister heben 提高癌症登记 "数据宝库 "的地位
Im Fokus Onkologie Pub Date : 2024-04-01 DOI: 10.1007/s15015-024-3811-8
Lamia Özgör
{"title":"Den „Datenschatz“ der Krebsregister heben","authors":"Lamia Özgör","doi":"10.1007/s15015-024-3811-8","DOIUrl":"https://doi.org/10.1007/s15015-024-3811-8","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140785027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Checkliste, um Nutzung alternativmedizinischer Angebote bei Krebserkrankten abzufragen 询问癌症患者使用替代医疗服务情况的清单
Im Fokus Onkologie Pub Date : 2024-04-01 DOI: 10.1007/s15015-024-3813-6
M. Borchers
{"title":"Checkliste, um Nutzung alternativmedizinischer Angebote bei Krebserkrankten abzufragen","authors":"M. Borchers","doi":"10.1007/s15015-024-3813-6","DOIUrl":"https://doi.org/10.1007/s15015-024-3813-6","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140778152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HCC: Durvalumab als Monotherapie zugelassen HCC：Durvalumab获批作为单药治疗
Im Fokus Onkologie Pub Date : 2024-04-01 DOI: 10.1007/s15015-024-3800-y
Andrea Warpakowski
{"title":"HCC: Durvalumab als Monotherapie zugelassen","authors":"Andrea Warpakowski","doi":"10.1007/s15015-024-3800-y","DOIUrl":"https://doi.org/10.1007/s15015-024-3800-y","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140794825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rezidivierendes Ovarialkarzinom: Benefit mit Maveropepimut-S Rezidivierendes Ovarialkarzinom：使用罂粟碱的益处
Im Fokus Onkologie Pub Date : 2024-04-01 DOI: 10.1007/s15015-024-3789-2
B. Fessler
{"title":"Rezidivierendes Ovarialkarzinom: Benefit mit Maveropepimut-S","authors":"B. Fessler","doi":"10.1007/s15015-024-3789-2","DOIUrl":"https://doi.org/10.1007/s15015-024-3789-2","url":null,"abstract":"","PeriodicalId":13436,"journal":{"name":"Im Fokus Onkologie","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140795202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信